Lataa...
Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies
Bruton’s tyrosine kinase (BTK) is a critical terminal enzyme in the B-cell antigen receptor (BCR) pathway. BTK activation has been implicated in the pathogenesis of certain B-cell malignancies. Targeting this pathway has emerged as a novel target in B-cell malignancies, of which ibrutinib is the fir...
Tallennettuna:
| Julkaisussa: | J Clin Med |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5920436/ https://ncbi.nlm.nih.gov/pubmed/29561760 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm7040062 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|